Dance Biopharm is a specialty biopharmaceutical company founded by Dr John Patton with a focus on developing products that enable insulin to be administered via the respiratory route. The company’s flagship product is the investigational Dance-501 insulin inhaler.
Dance Biopharm is focused on the development of inhaled insulin products to treat diabetes. Its main product, Dance-501, includes a liquid formulation of natural human insulin and a small silent handheld electronic aerosol device, intended to deliver the patient’s individualised dose of insulin in 1-3 breaths at mealtime.
The company is privately owned. It began operations in 2010 led by Dr John Patton, who has more than 20 years of experience in the development of inhaled insulin.